<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03784105</url>
  </required_header>
  <id_info>
    <org_study_id>S60496</org_study_id>
    <nct_id>NCT03784105</nct_id>
  </id_info>
  <brief_title>Codeine on Pharyngeal and Esophageal Motility</brief_title>
  <official_title>Effect of Codeine on Pharyngeal and Esophageal Motility in Healthy Subjects: a Double-blind, Placebo-controlled, Randomized, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioids act on opioid receptors located in the brain as well as in the gastrointestinal (GI)
      tract to induce changes in motility. A variety of studies have linked chronic opioid use with
      changes in intestinal and to a lesser extent esophageal motility. Less is known about acute
      administration effects on distal esophageal motility and LES and even less with respect to
      proximal esophagus, UES and pharynx. Codeine, an opioid receptor agonist, by acting both
      centrally as well as in the periphery may induce changes in parts of the GI tract implicated
      in deglutition. Therefore, to evaluate the hypothesis the researchers will study motility
      patterns in the pharynx, UES, proximal and distal esophagus and LES in 22 healthy volunteers
      receiving placebo or codeine (60 mg) in a double-blind randomized cross-over controlled
      fashion. Motility patterns will be studied using state-of-the-art criteria and analytic tools
      (Chicago 3.0, AIMPlot analysis).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2017</start_date>
  <completion_date type="Actual">December 14, 2018</completion_date>
  <primary_completion_date type="Actual">December 14, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo-controlled, randomized, cross-over study in healthy volunteers</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, preparation and administration of codeine or placebo conducted by an independent researcher.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in distal contractile integral</measure>
    <time_frame>1 week</time_frame>
    <description>The difference in distal contractile integral between the codeine and placebo condition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in integrated relaxation pressure</measure>
    <time_frame>1 week</time_frame>
    <description>The difference in integrated relaxation pressure between the codeine and placebo condition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in distal latency</measure>
    <time_frame>1 week</time_frame>
    <description>The difference in distal latency between the codeine and placebo condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in pressure flow</measure>
    <time_frame>1 week</time_frame>
    <description>The difference in pressure flow between the codeine and placebo condition</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Esophageal Motility Disorders</condition>
  <arm_group>
    <arm_group_label>Codeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Siripus simplex</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Codeine Phosphate</intervention_name>
    <description>30 mL of codeine phosphate 10mg/5mL</description>
    <arm_group_label>Codeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Siripus simplex</intervention_name>
    <description>Sugar syrup</description>
    <arm_group_label>Siripus simplex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers aged between 18-60 years old

          -  Written informed consent

        Exclusion Criteria:

          -  No chronic disease/medication

          -  No GI symptoms

          -  Not pregnant or breast-feeding

          -  No history of head/neck surgery

          -  Not allergic to codeine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jan Tack</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>December 21, 2018</last_update_submitted>
  <last_update_submitted_qc>December 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>codeine</keyword>
  <keyword>Esophageal motility</keyword>
  <keyword>Pharyngeal motility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Motility Disorders</mesh_term>
    <mesh_term>Esophageal Spasm, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Codeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

